Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of dosage of 17ß-estradiol on uterine growth in Turner syndrome - a randomized controlled clinical pilot trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Evaluation of Serum Insulin-like Factor 3 Quantification by LC-MS/MS as a Biomarker of Leydig Cell Function

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genetic variation at PPP1R3B increases hepatic CT attenuation and interacts with prandial status on plasma glucose

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1)

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Increases in bioactive IGF do not parallel increases in total IGF-I during growth hormone treatment of children born SGA

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Muscle-liver substrate fluxes in exercising humans and potential effects on hepatic metabolism

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Bone turnover markers during the remission phase in children and adolescents with type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lipidomic profiles, lipid trajectories and clinical biomarkers in female elite endurance athletes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Androgen insensitivity syndrome discovered due to discordance in prenatal assessments of fetal gender

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

CONTEXT: Most Turner syndrome (TS) girls need exogenous estrogen treatment to induce puberty and normal uterine growth. After puberty, the optimal estrogen treatment protocol has not been determined.

OBJECTIVE: To compare 2 doses of oral 17ß-estradiol on uterine size.

DESIGN: A double-blind, 5-year randomized controlled clinical trial.

SETTING: Ambulatory care.

PARTICIPANTS: Twenty young TS women (19.2 ± 2.5 years, range 16.0-24.9) participated. Sixteen patients completed the study. No patients withdrew due to adverse effects.

INTERVENTION: The lower dose (LD) group took 2 mg 17ß-estradiol/d orally and placebo. The higher dose (HD) group took 4 mg 17ß-estradiol/d orally.

MAIN OUTCOME MEASURE(S): Uterine volume evaluated by transabdominal ultrasound yearly.

RESULTS: Uterine size increased significantly more in the HD group compared with the LD group (P = 0.038), with a gain in uterine volume within the first 3 years of treatment of 19.6 mL (95% confidence interval [CI] = 4.0-19.0) in the HD group compared with 11.5 mL (95% CI = 11.2-27.9) in the LD group. The difference in 3-year gain was 8.1 mL (95% CI = 0.7-15.9). At the last visit, there were no significant differences in uterine volume between the groups.

CONCLUSION: HD oral 17ß-estradiol induces a steeper increase in uterine volume within the first years of treatment compared with the LD. However, the uterine growth potential seems to be the same in most young TS women making the duration of treatment equally significant as estrogen dose, although a few TS women did not experience sufficient uterine growth on 2 mg of estradiol.

CLINICALTRIALS.GOV: NCT00134745Abbreviations: BMI, body mass index; BSA, body surface area; DHEAS, dihydroepiandrosteronesulfate; HD, higher dose; HRT, hormone replacement therapy; LD, lower dose; TS, Turner syndrome; US, ultrasound.

Original languageEnglish
JournalThe Journal of clinical endocrinology and metabolism
Volume105
Issue number3
Pages (from-to)1-10
ISSN0021-972X
DOIs
Publication statusPublished - 1 Mar 2020

ID: 58139124